ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Abstracts from the 2016 AUA Convention
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Jinzang" data-source="post: 40321" data-attributes="member: 12925"><p>The abstract says:</p><p></p><p>A sample of 55 men using injectable T (cypionate or enanthate) for symptomatic hypogonadism at a single dose and frequency was selected for analysis from a single center mens health database. Age, T dosage, frequency of administration, duration of T therapy, and Hct were extracted through retrospective chart review. The cohorts were separated into 27 men on 200mg of T once weekly (QW) and 28 men on 80-160mg of T twice weekly (BIW). Indication for BIW dosing was a return of hypogonadal symptoms prior to the administration of the next dose. The maximum HCT was identified for each individual and the cohort mean of the maxima was calculated. The difference in numerical variables was assessed via Mann-Whitney U analysis. </p><p></p><p> No significant difference was identified between the mean (range) age of the QW and BIW cohorts (43.2 (27-63) years vs. 40.6 (27-62) years), respectively (p=0.36). Erythrocytosis occurred in 11% of the QW cohort with a maximum HCT (Interquartile Range) of 49.2 % (43.4, 54.6). In contrast, a maximum HCT of 51.4 % (45.7, 56.9) was observed in the BIW cohort, with 29% of men developing erythrocytosis. Statistical significance was identified in comparing the percent erythrocytosis of the two cohorts (p=0.007). The rate of erythrocytosis, defined as the number of days until maximum HCT while on testosterone, was comparable in both groups (p=0.18).</p></blockquote><p></p>
[QUOTE="Jinzang, post: 40321, member: 12925"] The abstract says: A sample of 55 men using injectable T (cypionate or enanthate) for symptomatic hypogonadism at a single dose and frequency was selected for analysis from a single center mens health database. Age, T dosage, frequency of administration, duration of T therapy, and Hct were extracted through retrospective chart review. The cohorts were separated into 27 men on 200mg of T once weekly (QW) and 28 men on 80-160mg of T twice weekly (BIW). Indication for BIW dosing was a return of hypogonadal symptoms prior to the administration of the next dose. The maximum HCT was identified for each individual and the cohort mean of the maxima was calculated. The difference in numerical variables was assessed via Mann-Whitney U analysis. No significant difference was identified between the mean (range) age of the QW and BIW cohorts (43.2 (27-63) years vs. 40.6 (27-62) years), respectively (p=0.36). Erythrocytosis occurred in 11% of the QW cohort with a maximum HCT (Interquartile Range) of 49.2 % (43.4, 54.6). In contrast, a maximum HCT of 51.4 % (45.7, 56.9) was observed in the BIW cohort, with 29% of men developing erythrocytosis. Statistical significance was identified in comparing the percent erythrocytosis of the two cohorts (p=0.007). The rate of erythrocytosis, defined as the number of days until maximum HCT while on testosterone, was comparable in both groups (p=0.18). [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Abstracts from the 2016 AUA Convention
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top